Cellular senescence as a therapeutic target to improve renal transplantation outcome
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
• Senescent cells secrete a range of pro-inflammatory factors and growth factors. • Chronically present senescent cells can negatively influence local milieu and organ function. • Senescent cells in renal grafts impair transplantation outcome. • Renal transplantation induces senescence. • The use of anti-senescence compounds to improve renal transplantation outcome is proposed. Kidney transplants from aged donors are more vulnerable to ischemic injury, suffer more from delayed graft function and have a lower graft survival compared to kidneys from younger donors. On a cellular level, aging results in an increase in cells that are in a permanent cell cycle arrest, termed senescence, which secrete a range of pro-inflammatory cytokines and growth factors. Consequently, these senescent cells negatively influence the local milieu by causing inflammaging, and by reducing the regenerative capacity of the kidney. Moreover, the oxidative damage that is inflicted by ischemia-reperfusion injury during transplantation can induce senescence and accelerate aging. In this review, we describe recent developments in the understanding of the biology of aging that have led to the development of a new class of therapeutic agents aimed at eliminating senescent cells. These compounds have already shown to be able to restore tissue homeostasis in old mice, improve kidney function and general health- and lifespan. Use of these anti-senescence compounds holds great promise to improve the quality of marginal donor kidneys as well as to remove senescent cells induced by ischemia-reperfusion injury. Altogether, senescent cell removal may increase the donor pool, relieving the growing organ shortage and improve long-term transplantation outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982 · cited 1×
“Aging can be described as the decline of physiological integrity ue to an accumulation of damage and deterioration of protein and rganelle function [3].”
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Aging with multimorbidity: A systematic review of the literature
Marengoni, A., Angleman, S., Melis, R., Mangialasche, F., Karp, A., Garmen, A., Meinow, B., & Fratiglioni, L. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.03.003 · Cited by 3,092
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954 · cited 1×
“To prevent the passage of DNA damage to daughter cells, the affected cells can undergo cell intrinsic cell death (apoptosis) or enter a state of permanent cell cycle arrest, called senescence [20,21].”
Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623 · cited 1×
“The establishment of senescence is a multi-step process that can take several days to complete [25].”
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 4×
“Dasatinib, a chemotherapeutic, an eliminate senescent fat cell progenitors [98].”
InfluentialCellular senescence in aging and age-related disease: from mechanisms to therapy
Childs, B. G., Durik, M., Baker, D. J., & van Deursen, J. M. (2015) · Nature Medicine · doi:10.1038/nm.4000 · Cited by 2,363
Hoeijmakers, J. H. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804615 · Cited by 2,239
Research works printed but not linked: 67
- Hazra, 2017, Determinants of health care costs in the senior elderly: age, comorbidity, impairment, or proximity to death?, Eur. J. Heal. Econ., 1
- Kontis, 2017, Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble, Lancet (Lond. Engl.), 389, 1323, 10.1016/S0140-6736(16)32381-9 · DOI · Paper page
- van Oostrom, 2014, Multimorbidity of chronic diseases and health care utilization in general practice, BMC Fam. Pract., 15, 61, 10.1186/1471-2296-15-61 · DOI · Paper page
- Hill, 2016, Global prevalence of chronic kidney disease – a systematic review and meta-analysis, PLoS One, 11, e0158765, 10.1371/journal.pone.0158765 · DOI · Paper page
- Weinstein, 2010, The aging kidney: physiological changes, Adv. Chronic Kidney Dis., 17, 302, 10.1053/j.ackd.2010.05.002 · DOI · Paper page
- Stevens, 2010, Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance, Adv. Chronic Kidney Dis., 17, 293, 10.1053/j.ackd.2010.03.010 · DOI · Paper page
- Heerspink, 2013, Novel drugs and intervention strategies for the treatment of chronic kidney disease, Br. J. Clin. Pharmacol, 76, 536, 10.1111/bcp.12195 · DOI
- Thiruchelvam, 2011, Renal transplantation, BMJ, 343, d7300, 10.1136/bmj.d7300 · doi:10.1136/bmj.d7300
- Agarwal, 2016, Defining end-stage renal disease in clinical trials: a framework for adjudication: table 1, Nephrol. Dial. Transplant., 31, 864, 10.1093/ndt/gfv289 · DOI
- Lim, 2013, Outcomes of kidney transplantation from older living donors, Transplant. J., 95, 106, 10.1097/TP.0b013e318277b2be · DOI
- Slegtenhorst, 2014, Mechanisms and consequences of injury and repair in older organ transplants, Transplantation, 97, 1091, 10.1097/TP.0000000000000072 · DOI
- Tasaki, 2014, Effect of donor–recipient age difference on long-term graft survival in living kidney transplantation, Int. Urol. Nephrol., 46, 1441, 10.1007/s11255-014-0655-8 · doi:10.1007/s11255-014-0655-8
- Oberhuber, 2012, Donor age-specific injury and immune responses, Am. J. Transplant., 12, 38, 10.1111/j.1600-6143.2011.03798.x · DOI
- Kurschat, 2016, Nierentransplantation im alter, Z. Gerontol. Geriatr., 49, 488, 10.1007/s00391-016-1118-x · DOI
- Braun, 2012, Cellular senescence limits regenerative capacity and allograft survival, J. Am. Soc. Nephrol., 23, 1467, 10.1681/ASN.2011100967 · DOI · Paper page
- Broude, 2007, p21Waf1/Cip1/Sdi1 mediates retinoblastoma protein degradation, Oncogene, 26, 6954, 10.1038/sj.onc.1210516 · DOI
- Coppé, 2010, The senescence-associated secretory phenotype: the dark side of tumor suppression, Annu. Rev. Pathol., 5, 99, 10.1146/annurev-pathol-121808-102144 · DOI · Paper page
- Hoffmann, 2015, NK cells of kidney transplant recipients display an activated phenotype that is influenced by immunosuppression and pathological staging, PLoS One, 10, e0132484, 10.1371/journal.pone.0132484 · DOI
- Morteau, 2010, Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo, PLoS One, 5, e13294, 10.1371/journal.pone.0013294 · DOI
- Franceschi, 2014, Chronic inflammation (Inflammaging) and its potential contribution to age-associated diseases, J. Gerontol. Ser. A Biol. Sci. Med. Sci., 69, 10.1093/gerona/glu057 · DOI · Paper page
- Bonventre, 2011, Cellular pathophysiology of ischemic acute kidney injury, J. Clin. Invest., 121, 4210, 10.1172/JCI45161 · DOI · Paper page
- Salvadori, 2015, Update on ischemia-reperfusion injury in kidney transplantation: pathogenesis and treatment, World J. Transplant., 5, 52, 10.5500/wjt.v5.i2.52 · DOI · Paper page
- McGlynn, 2009, Cellular senescence in pretransplant renal biopsies predicts postoperative organ function, Aging Cell, 8, 45, 10.1111/j.1474-9726.2008.00447.x · DOI · Paper page
- Melk, 2008, Effects of donor age and cell senescence on kidney allograft survival, Am. J. Transplant., 9, 114, 10.1111/j.1600-6143.2008.02500.x · DOI · Paper page
- Boonstra, 2004, Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells, Gene, 337, 1, 10.1016/j.gene.2004.04.032 · DOI · Paper page
- Hochegger, 2007, p21 and mTERT are novel markers for determining different ischemic time periods in renal ischemia-reperfusion injury, Am. J. Physiol. Renal Physiol., 292, F762, 10.1152/ajprenal.00084.2006 · DOI · Paper page
- Kailong, 2007, P53-Rb signaling pathway is involved in tubular cell senescence in renal ischemia/reperfusion injury, Biocell, 31, 213, 10.32604/biocell.2007.31.213 · DOI
- Seikrit, 2013, Biological responses to PDGF-AA versus PDGF-CC in renal fibroblasts, Nephrol. Dial. Transplant., 28, 889, 10.1093/ndt/gfs509 · doi:10.1093/ndt/gfs509
- Boor, 2014, PDGF and the progression of renal disease, Nephrol. Dial. Transplant., 29, i45, 10.1093/ndt/gft273 · DOI
- Lee, 2012, INK4a deletion results in improved kidney regeneration and decreased capillary rarefaction after ischemia-reperfusion injury, AJP Renal Physiol., 302, F183, 10.1152/ajprenal.00407.2011 · DOI · Paper page
- Nishioka, 2014, The cyclin-dependent kinase inhibitor p21 is essential for the beneficial effects of renal ischemic preconditioning on renal ischemia/reperfusion injury in mice, Kidney Int., 85, 871, 10.1038/ki.2013.496 · DOI
- DiRocco, 2014, CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury, AJP Renal Physiol., 306, F379, 10.1152/ajprenal.00475.2013 · DOI · Paper page
- Baar, 2017, Maintenance and repair of an aging life cycle, Oncotarget, 1–2
- Requião-Moura, 2015, Ischemia and reperfusion injury in renal transplantation: hemodynamic and immunological paradigms, Einstein, 13, 129, 10.1590/S1679-45082015RW3161 · DOI
- Dong, 2017, Alleviation of senescence and epithelial-mesenchymal transition in aging kidney by short-term caloric restriction and caloric restriction mimetics via modulation of AMPK/mTOR signaling, Oncotarget, 8, 16109, 10.18632/oncotarget.14884 · DOI
- Ning, 2013, Short-term calorie restriction protects against renal senescence of aged rats by increasing autophagic activity and reducing oxidative damage, Mech. Ageing Dev., 134, 570, 10.1016/j.mad.2013.11.006 · DOI
- Trepanowski, 2011, Impact of caloric and dietary restriction regimens on markers of health and longevity in humans and animals: a summary of available findings, Nutr. J., 10, 107, 10.1186/1475-2891-10-107 · DOI · Paper page
- van Ginhoven, 2010, Preoperative fasting induced protection against renal ischemia/reperfusion injury is independent of ghrelin in mice, Nutr. Res., 30, 865, 10.1016/j.nutres.2010.09.014 · DOI
- Jongbloed, 2014, Preoperative fasting protects against renal ischemia-reperfusion injury in aged and overweight mice, PLoS One, 9, e100853, 10.1371/journal.pone.0100853 · DOI
- Mitchell, 2010, Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in mice, Aging Cell, 9, 40, 10.1111/j.1474-9726.2009.00532.x · DOI · Paper page
- Shushimita, 2016, Protection against renal ischemia–reperfusion injury through hormesis? Dietary intervention versus cold exposure, Life Sci., 144, 69, 10.1016/j.lfs.2015.11.022 · DOI
- Tomé-Carneiro, 2013, Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence, Curr. Pharm. Des., 19, 6064, 10.2174/13816128113199990407 · DOI · Paper page
- An, 2016, Current understanding of metformin effect on the control of hyperglycemia in diabetes, J. Endocrinol., 228, R97, 10.1530/JOE-15-0447 · DOI · Paper page
- Wang, 2015, Metformin attenuated the inflammation after renal ischemia/reperfusion and suppressed apoptosis of renal tubular epithelial cell in rats, Acta Cir. Bras., 30, 617, 10.1590/S0102-865020150090000006 · DOI
- Arriola Apelo, 2016, An InhibiTOR of aging emerges from the soil of easter island, J. Gerontol. A. Biol. Sci. Med. Sci., 71, 841, 10.1093/gerona/glw090 · DOI · Paper page
- Li, 2017, A conserved NAD + binding pocket that regulates protein–protein interactions during aging, Science (80-.), 355, 1312, 10.1126/science.aad8242 · DOI · Paper page
- Yamamoto, 2014, Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion, PLoS One, 9, e98972, 10.1371/journal.pone.0098972 · DOI · Paper page
- Osorio, 2012, Nuclear lamina defects cause ATM-dependent NF- B activation and link accelerated aging to a systemic inflammatory response, Genes Dev., 26, 2311, 10.1101/gad.197954.112 · DOI · Paper page
- Veroux, 2011, Sirolimus in solid organ transplantation: current therapies and new frontiers, Immunotherapy, 3, 1487, 10.2217/imt.11.143 · DOI
- Conchon, 2011, Dasatinib – clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia, Rev. Bras. Hematol. Hemoter., 33, 131, 10.5581/1516-8484.20110034 · DOI
- Zhou, 2014, Kidney-targeted drug delivery systems, Acta Pharm. Sin. B, 4, 37, 10.1016/j.apsb.2013.12.005 · doi:10.1016/j.apsb.2013.12.005
- van der Horst, 2006, FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP, Nat. Cell Biol., 8, 1064, 10.1038/ncb1469 · DOI · Paper page
- Hosaka, 2004, Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification, Proc. Natl. Acad. Sci. U. S. A., 101, 2975, 10.1073/pnas.0400093101 · DOI · Paper page
- Martins, 2016, Long live FOXO: unraveling the role of FOXO proteins in aging and longevity, Aging Cell, 15, 196, 10.1111/acel.12427 · DOI · Paper page
- Sawyer, 2017, Protein domain mimics as modulators of protein–Protein interactions, Acc. Chem. Res., 50, 1313, 10.1021/acs.accounts.7b00130 · DOI
- Workman, 2007, Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer, Nat. Chem. Biol., 3, 455, 10.1038/nchembio0807-455 · DOI
- Bendell, 2016, A phase 2 study of the hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors, Cancer Invest., 34, 265, 10.1080/07357907.2016.1193746 · DOI
- Seggewiss-Bernhardt, 2015, Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma, Cancer, 121, 2185, 10.1002/cncr.29339 · DOI
- Socinski, 2013, A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer, Clin. Cancer Rancer Res., 19, 3068, 10.1158/1078-0432.CCR-12-3381 · DOI · Paper page
- Ferry, 1996, Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition, Clin. Cancer Res, 2, 659
- Askari, 2012, The effect of quercetin supplementation on selected markers of inflammation and oxidative stress, J. Res. Med. Sci., 17, 637
- Tolcher, 2015, Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors, Cancer Chemother. Pharmacol., 76, 1025, 10.1007/s00280-015-2883-8 · DOI
- Vlahovic, 2014, A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors, Invest. New Drugs, 32, 976, 10.1007/s10637-014-0116-3 · DOI
- Homme, 2017, Un-reborn again, QOTSA, 6
- McKay, 2012, Kidney transplantation and the ageing immune system, Nat. Rev. Nephrol., 8, 700, 10.1038/nrneph.2012.242 · DOI
- Tang, 2016, Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations, Expert Opin. Drug Metab. Toxicol., 12, 555, 10.1517/17425255.2016.1170808 · DOI · Paper page
- Sagiv, 2013, Immunosurveillance of senescent cells: the bright side of the senescence program, Biogerontology, 14, 617, 10.1007/s10522-013-9473-0 · DOI · Paper page
Cited by
Facing up to the global challenges of ageing
Partridge, L., Deelen, J., & Slagboom, P. E. (2018) · Nature · doi:10.1038/s41586-018-0457-8 · Cited by 1,475
Senolytic drugs: from discovery to translation
Kirkland, J. L., & Tchkonia, T. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13141 · Cited by 1,227
Cellular senescence and senolytics: the path to the clinic
Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01923-y · Cited by 1,134
Metadata
- Authors
- van Willigenburg, H., de Keizer, P. L. J., & de Bruin, R. W. F.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 130
- Pages
- 322-330
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2790614466
- Cited by
- 38
- References
- 49
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 113 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cellular senescence as a therapeutic target to improve renal transplantation outcome. https://app.cochat.ai/papers/10.1016/j.phrs.2018.02.015
- The paper
- van Willigenburg, H., de Keizer, P. L. J., & de Bruin, R. W. F. (2018). Cellular senescence as a therapeutic target to improve renal transplantation outcome. Pharmacological Research. https://doi.org/10.1016/j.phrs.2018.02.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.